- The Weekly D-Briefs
- Posts
- Thorne
Lesson: The right product at the wrong time is still the right product.
Most supplement brands operate on one assumption: consumers don't read closely enough to know the difference. Cheap formula, strong marketing, repeat. It worked for decades because the buyer had no way to verify what they were getting. Thorne ignored that playbook from day one. Founded in 1984, with four rounds of testing per product, NSF International certified manufacturing, a research partnership with the Mayo Clinic, and trusted by over 47,000 healthcare professionals and more than 100 professional sports teams. For most of its life, the brand was invisible to everyday consumers. Doctors ordered it. Clinicians recommended it. The general public had no idea it existed.
When Thorne went public, the stock market priced it like a generic vitamin company. L Catterton, one of the most respected consumer-focused private equity firms in the world, saw the mispricing immediately. They paid $680 million to take it private in 2023 at a 94% premium and shifted the strategy from healthcare professionals to direct consumers. According to CNBC, Thorne surpassed $500 million in revenue in 2025 with direct-to-consumer sales growing 63%, 7 million customers today versus 4 million at acquisition. Targeting $650 million in 2026. Exploring a sale at $4 billion. Nearly 6x entry in under three years.
The timing isn't luck. The Make America Healthy Again movement is putting every filler-heavy supplement brand under a microscope. A generation of consumers arrived who buy supplements for performance, better sleep, sharper focus, and faster recovery. They read labels. They want clinical evidence. The market Thorne was always built for finally showed up.
Where the Real Edge Lives
Half of Thorne's 7 million customers are on repeat subscriptions, not because of discounts, but because the product works consistently enough that they stop looking elsewhere. Most supplement brands at this scale are spending heavily just to earn basic consumer trust. Thorne came into the consumer market with that trust already intact from decades of healthcare professional endorsement. That's not a head start. That's a different race entirely.
Three Signals That Matter
Signal 1 - Founder/Operator Takeaway
The brands entering premium supplements today will spend years trying to manufacture clinical credibility. Thorne already has it, built through research partnerships and healthcare professional trust, before a single consumer ad ran. That foundation doesn't get replicated with a marketing budget.
Signal 2 - Consumer Insight
Sixty percent of Thorne's revenue now comes from consumers under 40, the most label-literate supplement buyer in history. They arrived skeptical of every other brand in the aisle. Thorne is the rare one that holds up under that scrutiny without having to change anything about what it already does.
Signal 3 - Investor/Market Lens
L Catterton sold Nutrafol to Unilever at over 10x revenue. Persona Nutrition went to Nestlé Health Science. The $4 billion exit target on Thorne is roughly 6x revenue, consistent with the track record. Named to TIME's 100 Most Influential Companies of 2026. That's not a branding exercise. That's the market finally agreeing with what the product always was.
That's my read on it from actually building in the CPG space.
Stick around. I’m just warming up.
Subscribe here for more → The Weekly D-Briefs (or forward this to someone building something meaningful)